Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Prothioconazole** is a systemic, broad-spectrum triazolinthione fungicide primarily used for the control of fungal diseases in cereal and other field crops. It acts as a **demethylation inhibitor (DMI)**, specifically inhibiting the fungal enzyme **sterol 14α-demethylase (CYP51)**, a cytochrome P450 enzyme essential for ergosterol biosynthesis, which is a key structural component of fungal cell membranes[1][5][13][16][18]. The fungicidal activity is predominantly attributed to its primary metabolite, **prothioconazole-desthio**, which potently and non-competitively inhibits CYP51 by binding to the heme group and preventing ergosterol formation, thus compromising fungal cell membrane integrity and function[5][18]. **Prothioconazole** is marketed as a solo active ingredient (e.g., Proline) and in various mixture products (e.g., Delaro Complete, Prosaro), controlling diseases such as Fusarium head blight, rusts, powdery mildew, and septoria leaf spot[3][16][18]. Developed by **Bayer CropScience** and introduced in 2004, it quickly became a key tool in cereal disease management[13].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on prothioconazole.